De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

摘要: To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied outcome 99 treatment-naive 17p- CLL from M. D. Anderson Cancer Center (n = 64) and Mayo Clinic 35). Among 67 asymptomatic followed for progression, 53% developed requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently stable disease, 19 progressing after follow-up up to 70 months. Risk factors progressive disease were Rai stage 1 or higher unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at higher, IgVH, in 25% more nuclei adverse survival. 3-year rates fewer, 2, these 95%, 74%, 22%, respectively (P < .001). Response therapy rituximab 6); purine analogues 25); analogues, rituximab, alemtuzumab 16) combinations 50%, 72%, 81%, respectively. exhibit heterogeneity, some experiencing an indolent course. Survival can be predicted using biologic characteristics.